

SUPPLEMENTAL MATERIAL


Table S1: Antibody Catalog Numbers

Antibody Name	Manufacturer	Catalog Number
Akt	Cell Signaling	9272
AMPK	Cell Signaling	2532
Angiostatin	Abcam	2904
Beta actin	Cell Signaling	4967
Connexin 43	Cell Signaling	83649
Desmin	Cell Signaling	4024
eNOS	Cell Signaling	32027
ERK1/2	Cell Signaling	4695
Filamin	Cell Signaling	4762
GAPDH	Cell Signaling	97166
Isolectin B4	Thermo Fisher Scientific	I32450
Jak2	Cell Signaling	3230
MCP-1	Cell Signaling	81559
MMP13	Cell Signaling	69926
mTOR	Cell Signaling	2972
p-Akt	Cell Signaling	4060
p-AMPK	Cell Signaling	2535
p-eNOS	Cell Signaling	9571
p-ERK1/2	Cell Signaling	4370
p-STAT3	Cell Signaling	9145
SMAD2/3	Cell Signaling	8685
SOD2	Cell Signaling	131415
STAT3	Cell Signaling	9139
TGFβ	Cell Signaling	3711
TIMP2	Cell Signaling	5738
Troponin I	Cell Signaling	13083
Troponin T	Cell Signaling	5593
Vimentin	Cell Signaling	5741
α-actinin	Cell Signaling	6487
α-fodrin	Cell Signaling	2122
α-SMA	Abcam	7817


Antibodies used in this study are listed along with corresponding manufacturer and catalog numbers. AMPK, 5' adenosine monophosphate-activated protein kinase; eNOS, endothelial nitric oxide synthase; ERK, extracellular regulated kinase 1/2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Jak2, janus kinase 2; MCP-1, monocyte chemoattractant protein-1; MMP13, matrix metalloproteinase 13; mTOR, mammalian target of rapamycin; p-, phosphorylated; STAT3, signal transducer and activator of transcription 3; SOD2; superoxide dismutase 2; TGFβ, transforming growth factor beta; TIMP2, tissue inhibitor of metalloproteinase 2; α-SMA, alpha smooth muscle actin.

FIGURE S1


AMPK



p-AMPK




p-eNOS




Total ERK1/2




p-ERK1/2




Total eNOS




Total Akt




p-Akt




Angiostatin



Jak2




TGFβ



SMAD2/3



p-STAT3




STAT3



SOD2




Alpha actinin




Alpha fodrin




Beta Actin



Connexin




Desmin




Filamin




MCP-1



MMP13




mTOR




TIMP2



Troponin I



Troponin T



Vimentin



Figure S1: Immunoblot uncropped images. Uncropped immunoblot images with molecular weights (in kilodaltons) labeled on left. AMPK, 5' adenosine monophosphate-activated protein kinase; eNOS, endothelial nitric oxide synthase; ERK, extracellular regulated kinase 1/2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Jak2, janus kinase 2; MCP-1, monocyte chemoattractant protein-1; MMP13, matrix metalloproteinase 13; mTOR, mammalian target of rapamycin; p-, phosphorylated; STAT3, signal transducer and activator of transcription 3; SOD2; superoxide dismutase 2; TGF β , transforming growth factor beta; TIMP2, tissue inhibitor of metalloproteinase 2.

FIGURE S2







Figure S2: Fibrosis-related western blot bands. Complete western blot bands displayed for protein quantification. Bands were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). MMP13, matrix metalloproteinase 13; TIMP2, tissue inhibitor of metalloproteinase 2; MCP-1, monocyte chemoattractant protein-1; mTOR, mammalian target of rapamycin.

FIGURE S3

TUNEL Staining



CON



CANA

Figure S3: Canagliflozin therapy has no effect on apoptosis in chronically ischemic myocardial tissue. There were no differences in percentage of apoptotic cells in ischemic myocardium as measured by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining between canagliflozin-treated pigs (CANA, n=8) and control (CON, n=8). Representative images of TUNEL staining in ischemic myocardial tissue shown. Upper and lower borders of box represent upper and lower quartiles, middle horizontal line represents median, upper and lower whiskers represent maximum and minimum values.